Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Arthritis Research UK has approved a 5-year renewal of the OA Centre.

The Arthritis Research UK Centre for Osteoarthritis (OA) Pathogenesis was first established in 2013 to identify new targets in the disease and create a seamless pipeline between laboratory discovery and clinical trials.

OA is the most common, yet one of the most neglected diseases of rheumatology, affecting over 8 million people in the UK. As with all diseases, it is important to understand the underlying pathways that drive the condition before drug treatments can be designed.

The Centre has had several successes in this area so far and has built an international reputation which has attracted excellent students, visiting workers and research fellows.

The Centre is delighted to receive further funding from Arthritis Research UK to continue this important work. Professor Tonia Vincent, Director of the Centre said:

"This grant has given us the opportunity to contribute to international efforts to understand early molecular pathways in OA. We are now in a position to move these forward to assess their suitability as targets in human disease. The next 5 years will be an exciting time for all of us and, we hope, a cause for optimism for our millions of OA sufferers."

Over the next five years, the Centre will focus its efforts in select areas of the disease, such as how tissues of the joint respond to injury, and on those areas where the Centre can expect to have the biggest impact, such as discovering new ways to image early damage in OA joints.

Although large scale clinical trials are still a little way off, the Centre believes that by the end of this grant, it will have tested two or three targets in groups of OA patients.

Similar stories

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards Funding

Oxford University has today been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

CRUK success for NDORMS researchers

Funding

Investigators based at the Kennedy Institute of Rheumatology, NDORMS have recently received CRUK awards to increase understanding of a variety of cancers and immunotherapy.

Kennedy Trust renews commitment to rheumatology research with £20M

Funding

The Kennedy Trust for Rheumatology Research (KTRR) has pledged a minimum of £20M over five years to the Kennedy Institute of Rheumatology at the University of Oxford to support pioneering research into chronic inflammatory disease.

Kennedy researchers awarded MRC funding for arthritis research

Funding

Congratulations to Kennedy researchers Professor Chris Buckley, Professor Mark Coles and Dr Stephen Sansom who have been awarded £1.5M funding from the Medical Research Council (MRC) to explore fibroblasts as an emerging target to treat chronic inflammatory disease.

Vaccine developed to treat osteoarthritic pain

Publication Research oacentre

Researchers have developed a vaccine that blocks the effects of the main cause of pain in osteoarthritis (OA) - nerve growth factor (NGF) - in mice.